Page 114 - 82_02
P. 114
Cannabinoid analogs in the treatment of pain 76. CADIME. Escuela Andaluza de Salud Pública.
Derivados del cannabis: papel en terapéutica. Rev.
64. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Soc Esp Dolor 2002;9: 401-4.
Huffman JW, et al. Cannabinoids control spasticity
and tremor in multiple sclerosis model. Nature. 77. Camí J, Farré M. Drug addiction. New Eng J Med
2000);404(6773): 84-7. 2003;349: 975-86.
65. Cadogan AK, Alexander SP, Boyd EA, Kendall DA. 78. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrié P.
Influence of cannabinoids on electrically evoked SR141716, a central cannabinoid (CB(1)) receptor
dopamine release and cyclic AMP generation in the antagonist, blocks the motivational and dopamine
rat striatum. J Neurochem 1997;69(3): 1131-7. releasing effects of bnicotine in rats. Behav Pharmacol
2002;13: 451-63.
66. Lastres-Becker I, Berrendero F, Lucas JJ, Martin-
Aparicio E, Yamamoto A, Ramos JA, et al. Loss of 79. Caillé S, Parsons LH. SR141716A reduces the
mRNA levels, binding and activation of GTP-binding reinforcing properties of heroin but not heroin-induced
proteins for 31 cannabinoid CB1receptors in the basal increases in nucleus accumbens dopamine in rats. Eur
ganglia of a transgenic model of Huntington's disease. J Neurosci 2003;18: 3145-9.
Brain Res 2002;929(2): 236-42.
80. Hungund BL, Szakall I, Adam A, Basavarajappa BS,
67. Wirguin I, Mechoulam R, Breuer A, Schezen E, Vadasz C. Cannabinoid CB1 receptor knockout mice
Weidenfeld J, Brenner T. Suppression of experimental exhibit markedly reduced voluntary alcohol
autoimmune encephalomyelitis by cannabinoids. consumption and lack alcohol-induced dopamine
Immunopharmacology 1994;28(3): 209-14. release in the nucleus accumbens. J Neurochem
2003;84: 698-704.
68. CADIME. Escuela Andaluza de Salud Pública.
Derivados del cannabis: papel en terapéutica. Rev Soc 81. Solinas M, Panlilio LV, Antoniou K, Pappas LA,
Esp Dolor 2002;9: 401-4. Goldberg SR. The cannabinoid CB1 antagonist N-
piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)
69. McKallip RJ, Lombard C, Martin BR, Nagarkatti M, -4-methylpyrazole-3-carboxamide (SR-141716A)
Nagarkatti PS. (9)-tetrahydrocannabinol-induced differentially alters the reinforcing effects of heroin
apoptosis in the thymus and spleen as a mechanism of under continuous reinforcement, fixed ratio, and
immunosuppression in vitro and in vivo. J Pharmacol progressive ratio schedules of drugself-administration
Exp Ther 2002;302: 451-65. in rats. J Pharmacol Exp Ther 2003;306: 93-102.
70. Ramírez BG, Blázquez C, Gómez del Pulgar T, 82. De Vries TJ, Homberg JR, Binnekade R, Raasø H,
Guzmán M, de Ceballos ML. Prevention of Schoffelmeer AN. Cannabinoid modulation of the
Alzheimer’s disease pathology by cannabinoids: reinforcing and motivational properties of heroin and
Neuroprotectin mediated by blockade of microglial heroin-associated cues in rats. Psychopharmacology
activation. J Neurosci 2005;25: 1904-13. 2003;168: 164-9.
71. Haas C, Selkoe DJ. A technical KO of amyloid-B 83. Fattore L, Spano MS, Cossu G, Deiana S, Fratta W.
peptide. Nature 1998;391(6665): 339-40. Cannabinoid mechanism in reinstatement of heroin-
seeking after a long period of abstinence in rats. Eur J
72. Benito C, Núñez E, Tolón RM, Carrier EJ, Rábano A, Neurosci 2003;17: 1723-6
Hillard CJ, Romero J. Cannabinoid CB2 receptors and
fatty acid amide hydrolase are selectively 84. Caillé S, Parsons LH. SR141716A reduces the
overexpressed in neuritic plaque-associated glia in reinforcing properties of heroin but not heroin-induced
Alzheimer’s disease brains. J Neurosci 2003;23: increases in nucleus accumbens dopamine in rats. Eur
11136-41. J Neurosci 2003;18: 3145-9.
73. Wade DT, Robson P, House H, Makela P, Aram J. A 85. Navarro M, Chowen J, Rocío A Carrera M, del Arco I,
preliminary controlled study to determine whether Villanúa MA. CB1 cannabinoid receptor antagonist-
whole-plant cannabis extracts can improve intractable induced opiate withdrawal in morphine-dependent
neurogenic symptoms. Clinical Rehab 2003;17(1): 21- rats. Neuroreport 1998;9: 3397-4402.
9.
86. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF,
74. Pinsger M, Schimetta W, Volc D, Hiermann E, Beslot F. Unresponsiveness to cannabinoids and
Riederer F y Pölz W. Benefits of an add-on treatment reduced addictive effects of opiates in CB1 receptor
with the synthetic cannabinomimetic nabilone on knockout mice. Science 1999;283: 401-4.
patients with chronic pain – a randomized controlled
trial. Wien Klin Worchenschr 2006;118(11-12): 327- 87. Nestler EJ. Molecular mechanisms of drug addiction.
35. Neuropharmacology 2004; 47 Suppl 1: 24-32.
75. Karst M, Salim K, Burstein S, Conrad I, Hoy L, 88. Rubino T, Forlani G, Viganò D, Zippel R, Parolaro D.
Schneider U. Analgesic effect of the synthetic Ras/ERK signalling in cannabinoid tolerance: from
cannabinoid CT-3 on chronic neuropathic pain: a behaviour to cellular aspects. J Neurochem 2005;93:
randomized controlled trial. JAMA 2003;290(13): 984-91.
1757-62.
89. Manzanares J, Corchero J, Romero J, Fernández-Ruiz
@Real Academia Nacional de Farmacia. Spain JJ, Ramos JA, Fuentes JA. Pharmacological and
229
